Regulation - Regulation, Almirall


Current filters:


Popular Filters

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland


UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

Aclidinium and formoterol fixed dose combo for COPD filed in Europe by Almirall


Spain’s largest drugmaker Almirall has filed a Marketing Authorization Application to the European…

aclidiniumAlmirallEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Forest Labs and Almirall opt to delay US filing for combo COPD drug


USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

IQWiG finds no added benefit proven for Constella in IBS


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsPharmaceuticalPricingRegulation

First approved new class of IBS-C therapy, Constella, now available in Europe


Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD)…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsMarkets & MarketingPharmaceuticalRegulation

Almirall pays GW Pharma milestone on Sativex; reports 1st-qtr results


UK-based GW Pharmaceuticals (AIM: GWP) says that it has received commercialization approval for its cannabinoid-based…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

The solution for Spanish pharma companies lies abroad


The pressure on the prices of medicines by Spanish government has seen the pharmaceutical market in Spain…


Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG


The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP


The European Medicines Agency last Friday issued a batch of recommendations relating to marketing authorization…

AlmirallBayerConstellaEuropeEyleaGastro-intestinalsIronwood PharmaceuticalsNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Almirall's aclidinium approved in Europe for COPD maintenance treatment


Spain's leading drugmaker, Almirall (ALM: MC) says that the European Commission has granted marketing…

aclidiniumAlmirallBretaris GenuairEklira GenuairEuropeMenariniPharmaceuticalRegulationRespiratory and Pulmonary

US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD


US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharma firm Almirall (ALM: MC,) which…

AlmirallForest LaboratoriesNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Spanish reforms and generics hit Almirall's 1st-qtr; Sativex progress


Spain's leading drugmaker Almirall (ALM: MC) has reported a 5.9% decrease in sales for the first quarter…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

No proof of added benefit of Sativex, says German IQWiG


In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingRegulationSativex

US FDA delays approval of Almirall and Forest Laboratories' COPD drug


The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain


German drug major Bayer (BAY: DE) and Norwegian partner Algeta (OSE: ALGETA) announced that the survival…

AlgetaAlmirallAlpharadinBayerCardio-vascularEuropeMarkets & MarketingOncologyPharmaceuticalRegulationResearchXarelto

GW Pharma’s Sativex cleared in Austria


The UK’s GW Pharmaceuticals’ (AIM: GWP) Sativex (delta-9-tetrahydrocannabinol (THC) and cannabidiol…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall


US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

Nycomed to market Almirall’s Kestine in Southeast Asia markets; files for linaclotide in EU


Swiss drug maker Nycomed, currently the subject of a 9.6 billion-euro takeover by Japan’s Takeda…

AlmirallAsia-PacificEuropeGastro-intestinalsLicensinglinaclotideNycomedPharmaceuticalRegulationRespiratory and Pulmonary

Back to top